Trial of Ginsenoside Compound K (GCK) Tablet in Patients With Rheumatoid Arthritis

Summary

This is a phase Ib study to investigate the safety, pharmacokinetics and preliminary efficacy of ginsenoside compound K (GCK) tablets in patients with rheumatoid arthritis. This study is to be run in China involving 10-12 sites. It will enroll approximately 240 patients to ensure 128 randomized with active rheumatoid arthritis. The treatment period is 12 weeks and total study duration per patient is approximately 14 weeks.

Timeline

Start

2017-03-16

Primary completion

2019-07-11

Completion

2019-12-11

Drugs

Indications